Please Subscribe to get a daily link to Pat's blog via email


Your privacy is important to us. We will never spam you and keep your personal data secure.


11 10, 2010

New Italian Study Shows Two Different Approaches To Treating Newly Diagnosed Multiple Myeloma Patients Both Work–But Stem Cell Transplants Still Achieve Highest Percentage Of Complete Response (CR)

Tags: , , , , |0 Comments

e-CancerMedicalScience/Oncology ran a story about the ESMO 35 Italian study Sunday:ESMO 35: High response rates seen in Phase-III trial of chemotherapy, new drug and stem cells in myelomaPublished: 10/10/2010 15:01:57 The first study of its kind comparing two different approaches to treating newly diagnosed multiple myeloma has found that both treatments achieved a positive response,

25 07, 2010

New Pomalidomide Study Available To Multiple Myeloma Patients Who’s Revlimid Has Stopped Working

Tags: , , , , , , , |0 Comments

Since it may be two or three years until Celgene's oral anti-myeloma novel therapy agent, pomalidomide, is approved by the FDA and widely available, patients with relapsed and/or refractory multiple myeloma may want to consider getting involved in a pomalidomide related clinical study.If you have tried Revlimid and it is no longer working you may

30 06, 2010

Europe Behind U.S. In Options For Myeloma Therapy

Tags: , , , |2 Comments

Here are the results from a study released this week at a large European Hematology Event in Barcelona, Spain.  I found this on a medical professionals only site, Pharmacy Europe:Phase III studies demonstrate significantly superior progression free survival with continuous revlimid therapy in diagnosed multiple myelomaMonday, June 28, 2010Data presented at the European Haematology Association’s annual congress in

1 05, 2010


Tags: , , , , , |4 Comments

My good friend at Millennium, Manisha Pai, forwarded me this press release about the new VISTA/Velcade study results last evening:-- Front-line use of VELCADE with melphalan and prednisone improves clinical benefit compared to conventional treatment --CAMBRIDGE, Mass., April 29, 2010 -- Millennium: The Takeda Oncology Company today announced the publication of results from the 682-patient,

24 01, 2010

Back To Basics: What Is Induction Therapy, & Why Is It Important For Treating Multiple Myeloma?

Tags: , , , , , |0 Comments

Recent e-mails have reminded me just how many newly diagnosed patients and/or caregivers log-on to this site each and every day.  Keeping this in mind, every week I am going to start a weekly series called "Back to Basics,"  designed to help bring our new readers up to speed.One question:  What is induction therapy?  According

16 01, 2010

Majestic Research Finds Hematologists/Oncologists Expect To Change Multiple Myeloma Treatment Practices Due To ASH 2009 Data

Tags: , , , , , , |0 Comments

Cancer Foundation for the World, Inc and Today's Healthy both featured stories about this today on their Websites:In a study published by Majestic Research's Market Research Group (formerly Rood Research), it was found that many hematologists and oncologists who attended the American Society of Hematology (ASH) 2009 Annual Meeting expect to change their multiple

6 12, 2009

European Myeloma Researchers Seem Behind The Times

Tags: , , , |0 Comments

Ouch! Another large myeloma drug study in the main auditoriam. The venue was full--over 4000 docs and clinitians--standing room only. Why? To listen to a Spanish study showing drug combination results with Velcade. Another damn melphalan/prednisone-based study! I need to pause here and ask you (and me!) to remember that European regulators seems far more